KAPA Stock Catalyst: Kairos Pharma Announces Safety Results from Phase 2 Trial of ENV-105 in Advanced Prostate Cancer

Jul 14, 2025 · 7:57pm ET

Results compared to Standard of Care Hormone Therapy.

Max move

+174.4%

High of day $13.16

Sparker timei

7:57pm ET

KAPA · Jul 14, 2025

CATALYST DATE · 1-MINUTE BARS

Catalyst Summary

Kairos Pharma, Ltd. (XASE: KAPA) announced safety results from a Phase 2 trial evaluating ENV-105 in patients with advanced prostate cancer. The trial assessed the safety profile of ENV-105.

The company reported the safety outcomes, noting the comparison to the Standard of Care Hormone Therapy. No specific amounts or filings were disclosed in the announcement.

This summary was generated by AI from public sources and may contain errors. Not financial advice. Trade at your own risk.

Real-time alerts

Get notified the next time KAPA sparks.

Download Sniper App →

Catch the next KAPA-style move in real time.

Day Trader Sniper alerts you the moment a setup like this triggers: premarket, open, or intraday.

Watch demo Download Free →